<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 15, 2020 (HealthDay News) — Regular aspirin use is associated with a lower risk for colorectal and other digestive tract cancers, according to a review published in the May 1 issue of the Annals of Oncology<\/i>.<\/p>\n
Cristina Bosetti, Ph.D., from the Istituto di Ricerche Farmacologiche Mario Negri IRCCS in Milan, and colleagues conducted a systematic review and meta-analysis of all observational studies evaluating the association between aspirin and cancers of the digestive tract sites, published through March 2019.<\/p>\n
The researchers found that regular aspirin use is associated with a reduced risk for colorectal cancer (relative risk [RR], 0.73 [95 percent confidence interval (CI), 0.69 to 0.78]; 45 studies), squamous cell esophageal cancer (RR, 0.67 [95 percent CI, 0.57 to 0.79]; 13 studies), adenocarcinoma of the esophagus and gastric cardia (RR, 0.61 [95 percent CI, 0.49 to 0.77]; 10 studies), stomach cancer (RR, 0.64 [95 percent CI, 0.51 to 0.82]; 14 studies), hepatobiliary tract cancer (RR, 0.62 [95 percent CI, 0.44 to 0.86]; five studies), and pancreatic cancer (RR, 0.78 [95 percent CI, 0.68 to 0.89]; 15 studies). There was no association with head and neck cancer (RR, 0.94 [95 percent CI, 0.76 to 1.16]; 10 studies). Findings were similar across sex, geographical areas, and other selected covariates. An aspirin dose of 75 to 100 mg\/day lowers the risk for colorectal cancer by 10 percent, while a dose of 325 mg\/day is associated with a 35 percent risk reduction. There was an inverse relationship noted between duration of aspirin use and risk reduction for all cancers, except head and neck cancers.<\/p>\n
“Taking aspirin for the prevention of bowel cancer, or any other cancers, should only be done in consultation with a doctor, who can take account of the person’s individual risk,” a coauthor said in a statement.<\/p>\n
The study was supported by Bayer.<\/p>\n